



Oncología personalizada de precisión: situación actual y perspectivas de futuro

Personalized Precision Oncology: current status and future perspectives

Madrid, 21 y 22 de marzo / March 21-22, 2019

BIO

Juan Carlos Lacal

Personal Statement

Research interest in Personalized Oncology focused in: mechanisms of malignant transformation, phospholipid metabolism and signalling in cancer, translational oncology, identification of new targets for precision medicine, anticancer drug design and discovery, design of novel anticancer strategies, identification of molecular biomarkers for the diagnosis and prognosis of cancer, and the prediction of response to standard and novel treatments.

Academic Training

BSc in Biology (1979), Universidad Autónoma, Madrid, Spain.

Ph.D. in Biochemistry and Molecular Biology (1982), Dept of Microbiology, Universidad Autónoma and Centro de Biología Molecular (CSIC), Madrid, Spain.

Postdoctoral training at the National Cancer Institute (NCI, Bethesda, MD) granted by the EMBO (1983-1984) and the Fogarty International Center (1985-1986).

Positions

Present Senior Scientist, Translational Oncology, Hospital Universitario de Fuenlabrada, Madrid, Spain (since October 2017)

1999-2014 Executive Editor, Clinical & Translational Oncology (official publication of the Spanish Federation of Cancer Societies)

2013-2013 Deputy Director. Division of Translational Oncology. Department of Oncology Health Research Institute and University Hospital "Fundacion Jimenez Diaz" Madrid, Spain

2002-2013 Professor of Research, CSIC (Spanish Research Council), Instituto de Investigaciones Biomedicas, Madrid, Spain.

2005-2010 Vicepresident of Research, Chief Scientific Officer (CSO) and President of the Scientific Advisory Board (SAB), Translational Cancer Drugs Pharma S.L. (TCD Pharma).

1989-2002 Senior Researcher (Investigador Científico), CSIC, Instituto de Investigaciones Biomedicas, Madrid. Since February, 1989

1989 Guest Researcher, Burroughs Wellcome Co., Department of Cell Biology, Research Triangle Park, North Carolina. Three months.

1987-89 Colaborador Científico, CSIC, Instituto de Investigaciones Biomedicas, Madrid.

1987-88 Visiting Associate, Laboratory of Cellular and Molecular Biology N.C.I., N.I.H., Bethesda, Maryland.

1985-86 Visiting Fellow, Laboratory of Cellular and Molecular Biology N.C.I., N.I.H., Bethesda, Maryland.

1983-84 Guest Researcher, Laboratory of Cellular and Molecular National Cancer Institute, N.I.H.

1980-82 PhD Program. Molecular biology of animal virus-infected cells: design of new antiviral approaches. Dept of Microbiology, Centro de Biología Molecular (CSIC), Madrid, Spain.

1978-79 Research Fellow. Dept of Microbiology, Autonoma University, Madrid, Spain.

1977 Collaborator in Technical Assistance, Dept of Microbiology, Autonoma University, Madrid, Spain.

Contributions to Science

Published 145 papers in SCI journals and 59 book chapters, articles in national journals and educational articles. H index= 56 (Google Scholar), more than 10,000 citations. Over 63 patents filled for 16 families since 1989.

Research Support and/or Scholastic Performance

Secretary General of the Spanish Association of Cancer Research (ASEICA). Jan 1991-Dec 1994.

President of the Spanish Association of Cancer Research (ASEICA). Jan 1995-Dec 1996.

Member of the Executive Committee of the Spanish Federation of Cancer Societies Jan 1991-Dec 1996.

Member of the Executive Committee of the European Association for Cancer Research (EACR). 1996-2000.

Member of the Council of the European Association for Cancer Research (EACR). 2007-2013

Chairman of the Council of the European Association for Cancer Research (EACR). 2011-2013

Organizer of multiple national and international meetings. Among many others, Chairman of the Organizing Committee of the Annual Meeting of the European Association for Cancer Research (EACR-17) and 9th National Meeting of ASEICA. Granada, June 8-11, 2002

Invited as speaker to more than 130 national and international meetings.

Inventor in 17 families of patents (over 60 patents filed).

Promoter scientist of three spin-off companies focused in oncology (one has completed a Phase I clinical trial of the first-in-human choline kinase inhibitor).